main navigation
MSGPP - Home
Project Description
  Flow Diagrams
Contact Information
  Program Project Members
Target Diseases & Organisms
* Malaria
   Plasmodium falciparum
   Plasmodium vivax
* Chagas' Disease
    [American Trypanosomiasis]
   Trypanosoma cruzi
* Sleeping Sickness
    [African Trypanosomiasis]
   Trypanosoma brucei
* Leishmaniasis
   Leishmania spp.
* Amoebiasis
   Entamoeba histolytica
* Giardiasis
   Giardia lamblia
* Toxoplasmosis
   Toxoplasma gondii
* Cryptosporidiosis
   Cryptosporidium parvum
Genome Databases
Target Progress
Ligand Screening
Papers by MSGPP
Related Links/Resources
MSGPP

LEISHMANIASIS
Leishmania spp.

Leishmaniasis has the potential to infect around 350 million people in eighty-eight countries in the tropics and subtropics. Leishmania epidemics have been reported in Northern India, the junction of Eritrea, Ethiopia and Sudan, and southern Europe. Current World Health Organization (WHO) estimates report 12 million people are infected with an annual incidence of two million. Leishmania can be subdivided into three categories: Cutaneous, Mucosal and Visceral Leishmaniasis. Visceral Leishmaniasis has been associated with HIV and is fatal if left untreated. These parasites are transmitted by sandflies and also display antigenic variation. Vaccination efforts have been unsuccessful and drug resistance is mounting.

Organism Leishmania spp.
At Risk 350 million - Tropics and Subtropics
Humans Infected 2 million
Disease Outcome Visceral form (25% above) fatal
Vaccine Prospects Poor - immune evasion
Available Drugs Toxic, difficult to deliver
Drug Resistance Documented

General Information: Medline, World Health Organization